GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Minapharm Pharmaceuticals (CAI:MIPH) » Definitions » Return-on-Tangible-Asset

Minapharm Pharmaceuticals (CAI:MIPH) Return-on-Tangible-Asset : 3.61% (As of Sep. 2024)


View and export this data going back to 2004. Start your Free Trial

What is Minapharm Pharmaceuticals Return-on-Tangible-Asset?

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Minapharm Pharmaceuticals's annualized Net Income for the quarter that ended in Sep. 2024 was E£394 Mil. Minapharm Pharmaceuticals's average total tangible assets for the quarter that ended in Sep. 2024 was E£10,932 Mil. Therefore, Minapharm Pharmaceuticals's annualized Return-on-Tangible-Asset for the quarter that ended in Sep. 2024 was 3.61%.

The historical rank and industry rank for Minapharm Pharmaceuticals's Return-on-Tangible-Asset or its related term are showing as below:

CAI:MIPH' s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -1.76   Med: 4.52   Max: 9.47
Current: -1.76

During the past 2 years, Minapharm Pharmaceuticals's highest Return-on-Tangible-Asset was 9.47%. The lowest was -1.76%. And the median was 4.52%.

CAI:MIPH's Return-on-Tangible-Asset is ranked worse than
65.17% of 1022 companies
in the Drug Manufacturers industry
Industry Median: 2.67 vs CAI:MIPH: -1.76

Minapharm Pharmaceuticals Return-on-Tangible-Asset Historical Data

The historical data trend for Minapharm Pharmaceuticals's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Minapharm Pharmaceuticals Return-on-Tangible-Asset Chart

Minapharm Pharmaceuticals Annual Data
Trend Dec22 Dec23
Return-on-Tangible-Asset
9.47 -0.43

Minapharm Pharmaceuticals Quarterly Data
Dec22 Jun23 Sep23 Dec23 Jun24 Sep24
Return-on-Tangible-Asset Get a 7-Day Free Trial 5.67 - -8.44 -4.25 3.61

Competitive Comparison of Minapharm Pharmaceuticals's Return-on-Tangible-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, Minapharm Pharmaceuticals's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Minapharm Pharmaceuticals's Return-on-Tangible-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Minapharm Pharmaceuticals's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where Minapharm Pharmaceuticals's Return-on-Tangible-Asset falls into.


;
;

Minapharm Pharmaceuticals Return-on-Tangible-Asset Calculation

Minapharm Pharmaceuticals's annualized Return-on-Tangible-Asset for the fiscal year that ended in Dec. 2023 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=-31.988/( (6468.915+8301.959)/ 2 )
=-31.988/7385.437
=-0.43 %

Minapharm Pharmaceuticals's annualized Return-on-Tangible-Asset for the quarter that ended in Sep. 2024 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Sep. 2024 )  (Q: Jun. 2024 )(Q: Sep. 2024 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Sep. 2024 )  (Q: Jun. 2024 )(Q: Sep. 2024 )
=394.324/( (10651.481+11213.102)/ 2 )
=394.324/10932.2915
=3.61 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Sep. 2024) net income data.


Minapharm Pharmaceuticals  (CAI:MIPH) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


Minapharm Pharmaceuticals Return-on-Tangible-Asset Related Terms

Thank you for viewing the detailed overview of Minapharm Pharmaceuticals's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Minapharm Pharmaceuticals Business Description

Traded in Other Exchanges
N/A
Address
El-Bardissi Street, 2T Takseem Asmaa Fahmy Street, Heliopolis, Cairo, EGY
Minapharm Pharmaceuticals is a company whose purpose is to produce medicines and chemicals. medical supplies. cosmetics, veterinary medicines, dental supplies, and the production of dietary supplements and herbal medicines. It produces drugs for many segments such as biogenetics, orthopedic, ophthalmology, miscellaneous, dermatology, gastroenterology, cardiology, and uro-gynaecology lines.

Minapharm Pharmaceuticals Headlines

No Headlines